抗程序性死亡配体1（PD-L1）阿替利珠单抗在一名接受透析的转移性尿路上皮细胞癌合并终末期肾病患者中的安全应用
Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis.
作者信息
Parisi Alessandro, Cortellini Alessio, Cannita Katia, Bersanelli Melissa, Ficorella Corrado
机构信息
Medical Oncology, St. Salvatore Hospital, L'Aquila, Italy.
Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Via Vetoio, 67100 L'Aquila, Italy.
出版信息
Case Rep Oncol Med. 2019 Feb 10;2019:3452762. doi: 10.1155/2019/3452762. eCollection 2019.
Anti-PD-L1 (programmed cell death-ligand 1) agents, such as atezolizumab, have been approved for the treatment of different advanced cancers. However, no study enrolled end-stage renal disease (ESRD) patients, and to our knowledge, there are no significant published data about safety and efficacy of PD-L1 inhibitors in this population. Here, we report the first case of a male patient with metastatic urothelial cell carcinoma and ESRD on dialysis, safely treated with atezolizumab.
抗程序性细胞死亡配体1（PD-L1）药物，如阿特珠单抗，已被批准用于治疗不同的晚期癌症。然而，尚无研究纳入终末期肾病（ESRD）患者，据我们所知，也没有关于PD-L1抑制剂在该人群中的安全性和有效性的重要公开数据。在此，我们报告首例患有转移性尿路上皮细胞癌且正在接受透析的ESRD男性患者，接受阿特珠单抗治疗后安全无虞。
Zotero 插件